VectorBuilder and Eureka Bio Form Alliance to Advance CGT Solutions Globally
China-based gene delivery technology developer VectorBuilder has formed a strategic alliance with compatriot firm Shenzhen...
Gene therapy
Gene Cradle’s GC310 Receives Tacit Approval from NMPA for Wilson’s Disease
Beijing-based gene therapy specialist Gene Cradle announced that it has received tacit clinical approval from...
YolTech Initiates Study for YOLT-204 in Transfusion-Dependent Beta-Thalassemia
Shanghai-based YolTech Therapeutics, a biotech startup specializing in lipid nanoparticle delivery and gene editing, has...
Belief BioMed’s BBM-D101 Receives FDA Approval for DMD Clinical Trial
China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced receiving clinical trial approval from...
Reforgene Medicine Secures Hundreds of Millions in Financing for Gene Therapy Expansion
Reforgene Medicine, a prominent gene editing therapy company headquartered in Guangzhou, has reportedly secured hundreds...
Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB
Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo...
HuidaGene Therapeutics Initiates HERO Trial for RNA-Editing Therapy HG204 in MECP2 Duplication Syndrome
Shanghai-based HuidaGene Therapeutics has announced the first subject dosing of the HERO clinical trial, which...
GRIT Biotechnology and Vitalgen BioPharma Partner on CRISPR-AaCas12bMAX Cell Therapies
China-based cell therapy specialists GRIT Biotechnology and Shanghai Vitalgen BioPharma Co., Ltd have entered into...
AccurEdit Therapeutics’ ART001 Shows Over 90% TTR Reduction in ATTR Amyloidosis Trial
Suzhou-based gene editing specialist AccurEdit Therapeutics has announced positive results from an ongoing investigator-initiated trial...
Lingyi Biotechnology and Jolly Pharmaceutical Ink Comprehensive Collaboration Agreement
China-based gene therapy specialist Lingyi Biotechnology Co., Ltd has entered into a comprehensive collaboration agreement...
Novartis Expands Gene Therapy Portfolio with Acquisition of Kate Therapeutics
Swiss pharmaceutical company Novartis (NYSE: NVS) has announced the acquisition of US-based Kate Therapeutics, Inc.,...
Frontera Therapeutics Receives FDA Approval for Phase II Study of FT-003 in nAMD
Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from...
Beijing Aims to Build a Leading Cell and Gene Therapy Hub by 2026 with New Action Plan
The Beijing Municipal Science & Technology Commission, in conjunction with the Administrative Commission of Zhongguancun...
Reforgene Medicine’s Gene Editing Therapy RM-101 Clears IND Hurdle for Usher Syndrome Treatment
Reforgene Medicine, a pioneer in gene editing therapy based in Guangzhou, has secured Investigational New...
Jiangsu Hengrui’s RGL-193 Receives NMPA Greenlight for Parkinson’s Disease Clinical Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China and listed as...
Belief BioMed Partners with Bayer’s AskBio to Explore New Gene Therapies
Belief BioMed Inc. (BBM), a Chinese biopharmaceutical company specializing in gene therapy, has announced a...
Frontera Therapeutics Receives FDA Approval for Phase II Study of First Chinese rAAV Gene Therapy
Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from...
Itcure Expands Gene Editing Reach with Collaborations in China’s Biotech Sector
Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with...
Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments
Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked...
Skyline Therapeutics’ Gene Therapy Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment
Skyline Therapeutics, a biopharmaceutical company based in China, has received Orphan Drug Designation (ODD) from...